capital raise

Apogee Therapeutics prices $350M offering at $70/share to fund development of inflammatory disease treatments, with lead candidate Zumilokibart targeting atopic dermatitis.

Harrow prices $50M in senior unsecured notes due 2030, expanding existing debt facility for product development and strategic initiatives.

Paranovus Entertainment raises $5M via direct offering of 14.3M shares at $0.35 each, closing March 25, 2026.

Abivax CEO dismisses acquisition rumors, plans equity and debt raise after Phase 3 obefazimod data in Q2 2026. $614.42M cash runway supports strategy.

Sol-Gel Technologies prices 459,112 shares at $72 each, raising $33.1M for SGT-610 development in Gorlin syndrome treatment.

Trio Petroleum shares fell 15.38% to $0.86 Monday after Trump's Iran strikes pause, though the company raised $19M in capital to fund Canadian and U.S. oil and gas expansion targeting 500-1,000 barrels daily production.

Reviva Pharmaceuticals closed a $10M public offering at $1.50/share to fund its RECOVER-2 Phase 3 schizophrenia trial, maintaining $23M cash through Q1 2027.

IREN's AI infrastructure capital raise triggers shareholder dilution concerns but may present buying opportunity if management executes expansion successfully.

Quantum BioPharma closes $3.75M debenture offering and settles $1.12M debt through equity issuance, strengthening balance sheet for business development.

Unusual Machines stock fell 15.6% after announcing a $150M share offering at $17, below the $18.60 closing price, diluting shareholders 22.6% despite strong cash reserves.

WeShop raises $2M from Performance Incentive Grant exercises, with $47M in vested grants remaining available as the company expands across North America.

Zealand Pharma raised DKK 955,071 through exercise of 10,530 employee warrants at DKK 90.70 per share, increasing total share capital to DKK 71,515,045.

Reviva Pharma raises $10M via share offering priced at $1.50 per share to fund Phase 3 schizophrenia drug trial through March 2026 closing.

Nebius raises $4 billion via convertible debt to fund AI data center expansion, capitalizing on GPU scarcity and its $17 billion Microsoft partnership.

SAB Biotherapeutics prices $85M offering at $3.85/share to fund Phase 2b trials of type 1 diabetes candidate SAB-142, with closing expected March 2026.

SAB Biotherapeutics prices $85M offering of shares and warrants to fund clinical trials for SAB-142, its lead type 1 diabetes candidate.

CytomX Therapeutics prices $250M stock offering at $5.30/share to fund Varseta-M development and pipeline advancement, closing March 2026.

Nebius stock fell 10.78% after announcing a $3.75 billion convertible debt offering to finance AI infrastructure expansion, despite securing major partnerships with Microsoft, Nvidia, and Meta.

Jayud Global Logistics prices registered direct offering of 5.03M shares at $1.34 each, raising $6.73M for working capital and overseas expansion.

Aureus Greenway (AGH) closes $9M private placement, issuing 3M shares at $3/share to fund working capital and proposed Autonomous Power Corporation merger.